Literature DB >> 2501064

Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant.

T K Nilsson1, E Löfvenberg.   

Abstract

Over a 6-year period, 10 patients with lupus anticoagulant activity were seen. A history of thrombotic disease was found in 6 patients, but only 3 had systemic autoimmune disease. Reduced fibrinolytic activity after venous occlusion was found in 9 subjects, but only 4 had high von Willebrand factor levels. These changes were unrelated to inflammatory activity, which was ruled out by normal serum protein electrophoresis in all but one case. Human brain thromboplastin dilution test was pathological in all subjects with depressed fibrinolytic activity. These two tests may prove to be of value to single out those LA patients with highest risk for development of thromboembolic disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501064     DOI: 10.1007/bf02031071

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

Review 1.  Lupus-like anticoagulants, modulation of the protein C pathway and thrombosis.

Authors:  J M Freyssinet; J P Cazenave
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

2.  Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis.

Authors:  C Korninger; K Lechner; H Niessner; H Gössinger; M Kundi
Journal:  Thromb Haemost       Date:  1984-10-31       Impact factor: 5.249

3.  "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation.

Authors:  L O Carreras; J G Vermylen
Journal:  Thromb Haemost       Date:  1982-08-24       Impact factor: 5.249

4.  Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage.

Authors:  E Angles-Cano; Y Sultan; J P Clauvel
Journal:  J Lab Clin Med       Date:  1979-08

5.  Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  D B Cines; A P Lyss; M Reeber; M Bina; R J DeHoratius
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

6.  Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis.

Authors:  G Mellbring; T Nilsson; N Bergsdorf; P Wallén
Journal:  Thromb Res       Date:  1984-11-15       Impact factor: 3.944

7.  Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases.

Authors:  D A Gastineau; F J Kazmier; W L Nichols; E J Bowie
Journal:  Am J Hematol       Date:  1985-07       Impact factor: 10.047

8.  The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant.

Authors:  P M Mannucci; M T Canciani; D Mari; P Meucci
Journal:  Scand J Haematol       Date:  1979-05

9.  Plasminogen activator release during venous stasis and exercise as determined by a new specific assay.

Authors:  B Wiman; G Mellbring; M Rånby
Journal:  Clin Chim Acta       Date:  1983-01-24       Impact factor: 3.786

10.  Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity.

Authors:  M H Rustin; H A Bull; S J Machin; D A Isenberg; M L Snaith; P M Dowd
Journal:  J Invest Dermatol       Date:  1988-05       Impact factor: 8.551

View more
  3 in total

1.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

2.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

3.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.